Mineralys Therapeutics (MLYS) Q2 2026 earnings summary

Executive summary

• Focused on commercial launch readiness and clinical development of lorundrostat for uncontrolled/resistant hypertension, with a PDUFA date set for December 22, 2026.

• Welcomed Dr. Terry Ferguson as Chief Medical Officer to lead late-stage clinical activities.

• Completed six clinical trials supporting lorundrostat’s efficacy and safety, with ongoing open-label extension for long-term data.

• Strengthened balance sheet and lorundrostat economics through royalty repurchase, capital raises, and financing initiatives.

• No product revenue to date; operations funded by equity, debt, and licensing.

Financial highlights

• Ended Q2 2026 with $661.4 million in cash, cash equivalents, and investments, up from $656.6 million at year-end 2025.

• R&D expenses rose to $221.4 million from $38.3 million year-over-year, mainly due to a $200 million upfront payment to Tanabe.

• G&A expenses increased to $24.7 million from $8.5 million, driven by higher professional fees and personnel costs.

• Net loss for Q2 2026 was $241.1 million, compared to $43.3 million in Q2 2025, reflecting increased investment in strategic initiatives.

• Net loss per share was $2.85 for Q2 2026; weighted-average shares outstanding were 84.7 million.

Outlook and guidance

• Cash and investments expected to fund planned operations, including commercial launch, into 2028.

• Anticipates increased expenses for regulatory, commercial, and organizational build-out ahead of potential approval.

• Future capital needs depend on regulatory outcomes, commercialization, and market acceptance.

• Commercial launch preparations are on track, with sales organization to be established before the PDUFA date.